Neogen (Neogen) Risk Assessment

View and export this data going back to 1989. Start your Free Trial

What is Neogen Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Neogen is: High Risk: Good fundamentals, beware of shrinking business.

Competitive Comparison of Neogen's Risk Assessment

For the Diagnostics & Research subindustry, Neogen's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Neogen's Risk Assessment Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Neogen's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Neogen's Risk Assessment falls into.

Neogen (NAS:NEOG) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Neogen Risk Assessment Related Terms

Thank you for viewing the detailed overview of Neogen's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Neogen (Neogen) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Neogen Corp (NAS:NEOG) » Definitions » Risk Assessment

Comparable Companies

SHC RDNT GH NEO TWST MYGN VCYT OPK LAB FLGT TSE:2309 TMO DHR IQV IDXX XSWX:LONN A MTD ICLR ILMN

Traded in Other Exchanges

NG2:Germany NG2:Germany

Address

620 Lesher Place, Lansing, MI, USA, 48912

Website

https://www.neogen.com

Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety. In food safety (70% of post-merger sales), Neogen performs diagnostics to detect unintended substances in food and animal feed, such as pathogens, allergens, and drug residues, for food and feed processing companies. In animal safety (20% of post-merger sales), Neogen sells veterinary instruments, pharmaceuticals, disinfectants, and genomics tests for animals, including cattle, horses, and canines. Sales in the United States account for 60% of total revenue, while international markets, including Canada, Europe, Asia, and Latin America, account for the remaining 40%.

Executives

William T Boehm	director
Douglas Edward Jones	officer: Vice President, CCO	620 LESHER PLACE, LANSING MI 48912
Jason Warren Lilly	officer: Vice President	620 LESHER PLACE, LANSING MI 48912
James P Tobin	director	620 LESHER PLACE, LANSING MI 48895
David H. Naemura	officer: VP & CFO	C/O GATES INDUSTRIAL CORPORATION PLC, 1144 FIFTEENTH STREET, SUITE 1400, DENVER CO 80202
Amy M Rocklin	officer: Chief Legal & Reg. Officer	620 LESHER PLACE, LANSING MI 48912
Steven J. Quinlan	officer: VP & CFO	620 LESHER PLACE, LANSING MI 48912
Jeffrey D Capello	director	C/O NEOGEN CORP., 620 LESHER PLACE, LANSING MI 48912
Aashima Gupta	director	C/O NEOGEN CORPORATION, 620 LESHER PLACE, LANSING MI 48912
John Edward Adent	officer: Chief Executive Officer	822 7TH STREET, SUITE 740, GREELEY CO 80631
Darci L Vetter	director	620 LESHER PLACE, LANSING MI 48912
Ronald D Green	director	620 LESHER PLACE, LANSING MI 48912
James C Borel	director	1007 MARKET STREET, WILMINGTON DE 19898
Terri A Morrical	officer: General Manager
G Bruce Papesh	director	726 APPLEGATE LANE, EAST LANSING MI 48823